NASDAQ OMX

KLOX Technologies reports on final results from its clinical study on LumiHeal(TM) for the treatment of chronic wounds

3.5.2017 16:30 | NASDAQ OMX

Dela

LAVAL, Quebec, May 03, 2017 (GLOBE NEWSWIRE) -- Today, the final results on KLOX Technologies' (Klox) EUREKA study, which evaluated LumiHeal in the treatment of hard-to-heal, non-responsive, chronic wounds, were reported at the European Wound Management Association, in Amsterdam.

LumiHeal is a CE marked, first-in-class, proprietary, non-thermal and non-invasive treatment solution that utilizes hyper pulsed fluorescence light (HPFL) to treat acute and chronic wounds.

"LumiHeal has shown that it is a viable and effective treatment solution for patients with debilitating hard-to-heal, chronic wounds," stated Dr. Marco Romanelli, MD, PhD, Associate Professor of Dermatology at the School of Medicine, University of Pisa, and Chief of the Wound Healing Research Unit, and President Elect of the World Union of Wound Healing Societies. "LumiHeal represents a new option in the way practitioners can manage and treat hard-to-heal chronic wounds." 

"We are very pleased that the data released today confirmed the interim analysis reported in September 2016 on 33 patients," said Dr. Michel Cimon, MD, Senior Vice President, Chief Medical and Scientific Officer at Klox. "It's an important day for LumiHeal and for FB Advanced Wound Care, our wound care franchise."

Clinical final results from EUREKA study on LumiHeal(TM) and chronic wounds management

Professor Marco Romanelli reported the final study results on the evaluation of real-life use of LumiHeal in Chronic Wounds Management (Venus Leg Ulcers, Diabetic Foot Ulcers, and Pressure Ulcers). The results reported were on 99 patients who completed treatment in the EUREKA study.

Investigators' final analysis supports the strong efficacy profile of LumiHeal in promoting wound closure along with wound bed preparation in hard-to-heal chronic wounds. These results indicate LumiHeal's ability, in a majority of cases, to transition hard-to-heal, non-responsive, chronic wounds into an acute wound setting.   

Investigators found the treatment to be safe, easy to administer and very well tolerated by the subjects' population. Compliance to the study visits was excellent.

The excellent tolerability and compliance profiles is reinforced by the positive action on pain reduction observed during this study, especially in the VLU population.

Final results show:

Out of the 99 patients reported, 71% of them had a prognosis factor of poor healing at study entry;

The average treatment duration for all types of wounds was 80.5 days;

47 of these hard-to heal, chronic wounds, closed completely during the study period VLUs (26), DFUs (16), PU (5);

96% of wounds that closed completely, remained closed throughout the follow up period;

69.2% of VLUs and 68.8% of DFUs were ready for skin graft according to clinician's opinion;

The table below summarizes the top line data:

  Median
Wound Age
(Months)
Total Wounds
Treated
Total Wounds
Closed
Median
baseline area
(cm(2))
Median area
at last Study
visit
(cm(2))
p-value
VLU 9.3 52 32 6.85 0.40 <0.001
DFU 4.0 32 16 1.60 0.35 0.001
PU 12.5 15 5 1.90 1.20 0.268

The final results of the EUREKA study show, that taken together with efficacy, treatment ease of use, safety, and a positive impact on pain reduction, LumiHeal has the ability to become a leading option for the treatment and management of hard-to-heal, chronic wounds.

About LumiHeal(TM)
LumiHeal is a CE marked, first-in-class, proprietary, non-thermal and non-invasive treatment solution that generates hyper pulsed fluorescence light to treat acute and chronic wounds. It is used in conjunction with a multi-LED light. LumiHeal is a topical gel comprising of light absorbing molecules, which is applied to a wounded area. The HPFL generated have the capacity to penetrate various depths of the skin (epidermis, dermis, hypodermis). Treatment duration lasts only a number of minutes, while maintaining a safe and well tolerated product profile.

About KLOX Technologies
Klox is a specialty pharmaceutical company focused on developing and commercializing products based on its proprietary Fluorescence Biomodulation technology platform, previously known as BioPhotonics, to address skin and soft tissue disorders. Klox is advancing its programs as part of its multiple franchises focusing on indications across Dermatology, Wound Care, and Oral Health. For more information and to consult the abstracts, please visit www.kloxtechnologies.com.

Forward Looking Statements
Certain statements contained in this newswire, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward looking statements include those regarding cosmetics and medical devices and medical applications and clinical trials and the status and related results thereto, as well those regarding continuing and further development and commercialization efforts. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Klox Technologies Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the medical, cosmetics and/or consumer goods industries, changes in the regulatory environment in the jurisdictions in which Klox Technologies Inc. does business, financial and commercial markets volatility, fluctuations in costs, and changes to the competitive environment, as well as other risks. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing and further development efforts, specific risks which could cause actual results to differ materially from Klox Technologies Inc.'s current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our products, final and quality controlled verification of data and the related analyses, and the expense and uncertainty of obtaining regulatory approval.

For more information:
Jade Lavallée Labossière
Hill+Knowlton Strategies
514-375-2730
Jade.lavallee-labossière@hkstrategies.ca




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: KLOX Technologies Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

TGS and PGS Announce Fourth 3D Seismic Project Offshore Eastern Canada26.5.2017 07:50

ASKER, Norway, May 26, 2017 (GLOBE NEWSWIRE) -- TGS and Petroleum Geo-Services (&quot;PGS&quot;) announce the fourth 3D seismic project offshore Eastern Canada for 2017. Long Range 3D will comprise approximately 9,100 km2 of 3D GeoStreamer® data in the Eastern Newfoundland region. The survey covers open acreage which will be included in the November 2018 licensing round under Newfoundland and Labrador's Scheduled Land Tenure system. Following completion of these surveys, the jointly-owned library will have more than 175,000 km of 2D GeoStreamer data and 28,500 km2 of 3D GeoStreamer data. An expansive well log library is also available in the region, along with advanced multi-client interpretation products that will improve play, trend and prospect delineation. &quot;With four 3D projects now committed for 2017 this will be our most active year ever in Newfoundland and Labrador. E&amp;P companies are continuing to prioritize this region in their exploration strat

Mandalay Resources Corporation går ut med slutförande av reviderat Återköpserbjudande och begäran om medgivande gällande 5,875 % säkerställda utbytbara skuldebrev25.5.2017 13:46

TORONTO 24 maj 2017 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (&quot;Mandalay&quot; eller &quot;Bolaget&quot;) (TSX:MND) meddelade idag att Gold Exchange Limited (&quot;GEL&quot;), ett självständigt företag för särskilda ändamål som är registrerat i Jersey, har ingått avtal gällande ett reviderat återköpserbjudande (&quot;Återköpet&quot;) och en begäran om medgivande (&quot;Begäran om medgivande&quot;) för sitt kapitalbelopp på 60 000 000 USD, 5,875 % säkerställda utbytbara skuldebrev som löper ut 2019 (&quot;Skuldebreven&quot;). GEL gav ut Skuldebreven 2014 och lånade ut inkomsterna till ett av Bolagets dotterbolag i enlighet med villkoren för låneavtalet och relaterad finansieringsöverenskommelse (&quot;Lånet&quot;) som tillsammans speglar de huvudsakliga villkoren för Skuldebreven. Som angivet i Mandalays pressmeddelande från den 12 maj 2017, slutfördes inte det ursprungliga återköpserbjudandet och begäran om medgivande som GEL lanserade gällande Skuldebreven

Karolinska Development's Annual General Meeting 201724.5.2017 20:00

STOCKHOLM - May 24, 2017. At the Annual General Meeting of Karolinska Development AB held May 24, 2017, the following resolutions were passed: Profit and loss statement and the balance sheet: It was resolved to adopt the profit and loss statement and the balance sheet and the consolidated profit and loss statement and the consolidated balance sheet. Appropriation of the company's result: It was resolved to approve the allocation of the result, proposed by the board and the CEO, in total SEK -12 406 768 be allocated as follows: To be carried forward SEK -12 406 768. Discharge from liability of the directors and the CEO: It was resolved to grant the directors and the CEO discharge from liability for the financial year 2016. Resolution regarding the number of directors and auditors and deputy auditors to be appointed: It was resolved that the number of directors shall be seven without deputies and that the number

Karolinska Developments årsstämma 201724.5.2017 20:00

STOCKHOLM den 24 maj 2017. Vid Karolinska Developments årsstämma som hölls den 24 maj 2017 beslutade aktieägarna, följande: Redovisning: beslutades att fastställa av resultaträkning och balansräkning samt koncernresultaträkning och koncernbalansräkning. Resultatdisposition:  beslöts att godkänna styrelsens och verkställande direktörens förslag att till årsstämmans förfogande stående medel, sammanlagt SEK -12 406 768, disponeras enligt följande: SEK -12 406 768 balanseras i ny räkning. Ansvarsfrihet för styrelsens ledamöter och VD: beslöts att bevilja styrelsen och verkställande direktören ansvarsfrihet för verksamhetsåret 2016. Fastställande av antalet styrelseledamöter samt revisorer och revisorssuppleanter: Beslöts att antalet ledamöter i styrelsen skall vara sju utan suppleanter samt att antalet revisorer skall vara en utan suppleanter. Fastställande av arvoden till styrelsen och revisorerna: bes

Nasdaq to Deliver Post-Trade Technology to Depósito Central de Valores (DCV)24.5.2017 15:00

The Chilean central securities depository (CSD) will boost its infrastructure capabilities and increase efficiencies with fully-fledged CSD solution based on the Nasdaq Financial Framework NEW YORK and SANTIAGO, Chile, May 24, 2017 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) and Depósito Central de Valores (DCV)  today announced a new landmark agreement to bolster the technological infrastructure of Chile's central securities depository (CSD). &quot;We are very satisfied with our thorough, year-long vendor partnership process in selecting the Nasdaq platform, which will replace the core system of the DCV,&quot; said Fernando Yáñez, CEO of DCV. &quot;We believe with the implementation of this new system, we will have more opportunities for growth and diversification in our current services, as well as strengthening our day-to-day operations.&quot; Under the agreement with DCV, Nasdaq will deliver its CSD Solution, which will allow for:

Mandalay Resources Corporation Announces Completion of Revised Repurchase Offer and Consent Solicitation in Respect of 5.875% Secured Exchangeable Bonds24.5.2017 14:11

TORONTO, May 24, 2017 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (&quot;Mandalay&quot; or the &quot;Company&quot;) (TSX:MND) announced today that Gold Exchange Limited (&quot;GEL&quot;), an unaffiliated special purpose vehicle incorporated in Jersey, has entered into agreements with respect to a revised repurchase offer (the &quot;Repurchase&quot;) and consent solicitation (the &quot;Consent Solicitation&quot;) in respect of its U.S.$60,000,000 principal amount 5.875% secured exchangeable bonds due 2019 (the &quot;Bonds&quot;). GEL issued the Bonds in 2014 and loaned the proceeds to a subsidiary of the Company pursuant to the terms of a loan agreement and related funding agreement (the &quot;Loan&quot;) which together mirror the principal terms of the Bonds. As indicated in Mandalay's press release of May 12, 2017, the original repurchase offer and consent solicitation that GEL launched in respect of the Bonds on April 19, 2017 (the &quot;Original Proposed

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt nyhetsrum